Table 2 Example quality indicators for each center/module type
Center/module | Quality indicator definition | Target value | Sites meeting the target in 2015 | Median | Source |
|---|---|---|---|---|---|
Breast | Pretreatment histological confirmation (numerator: patients with pretreatment histological diagnosis confirmation by means of a punch or vacuum biopsy; population: patients with initial procedure and histology showing invasive breast cancer or DCIS as primary disease) | ≥ 90% | 97.5% (268/275) | 97.6% | Annual Report of Certified Breast Cancer Centers 2016 —Quality Indicators (in English) doi:10.13140/RG.2.1.1805.7204 |
Colorectal | Quality of the TME rectum specimen (information from pathology; numerator: patients with good to moderate quality TME [grade 1: mesorectal fascia or grade 2: intramesorectal excisions]; population: patients with radically operated rectal cancer) | ≥ 70% | 98.5% (257/261) | 95.2% | Annual Report of Certified Colorectal Cancer Centers 2016 — Quality Indicators (in English) doi:10.13140/RG.2.1.3771.8001 |
Prostate | Percutaneous radiotherapy with hormone ablation therapy for locally confined prostate carcinoma with high risk (numerator: primary cases with additional neoadjuvant and/or adjuvant hormone ablation therapy; population: primary cases with prostate carcinoma T1–2 N0 M0 with high risk (PSA > 20 ng/mL or Gleason score ≥ 8 or clinical stage T2c) and percutaneous radiotherapy | No target in 2015 | – | 71.43% (93 sites) | Annual Report of Certified Prostate Cancer Centers 2016 — Quality Indicators (in English) doi:10.13140/RG.2.1.3673.4969 |
Lung | Combined chemoradiotherapy in stage IIIA4/IIIB (numerator: combined chemoradiotherapy in NSCLC primary cases in stage IIIA4/IIIB with ECOG 0/1; population: NSCLC primary cases in stage IIIA4/IIIB | No target in 2015 | – | 39.6% | Annual Report of Certified Lung Cancer Centers 2016 — Quality Indicators (in German) doi:10.13140/RG.2.1.3998.6327 |
Skin | Malignant melanoma: sentinel-node biopsy (SNB, numerator: primary cases in which SNB was carried out; population: primary cases of primary cutaneous melanoma with a tumor thickness of ≥1 mm and no evidence of locoregional or distant metastasis) | ≥ 80% | 72.7% (32/44) | 85.2% | Annual Report of Certified Skin Cancer Centers 2016 — Quality Indicators (in German) doi:10.13140/RG.2.1.2227.2408 |
Ovary | Postoperative chemotherapy for advanced ovarian carcinoma (numerator: primary surgical cases of FIGO IIB–IV ovarian carcinoma with postoperative chemotherapy; population: primary surgical cases of FIGO IIB–IV ovarian carcinoma and chemotherapy) | No target in 2015 | – | 96.4% | Annual Report of Certified Gynecological Cancer Centers 2016 — Quality Indicators (in German) doi:10.13140/RG.2.1.1052.0568 |
Cervix | Histological confirmation | No target in 2015 | – | 100.0% | Annual Report of Certified Gynecological Cancer Centers 2016 — Quality Indicators (in German) doi:10.13140/RG.2.1.1052.0568 |
Head–neck | Imaging in patients with oral cavity carcinoma to determine N category (numerator: patients with CT or MRI examinations of the region from the cranial base to the superior thoracic aperture to determine the N category; population: primary cases of patients with oral cavity carcinoma) | No target in 2015 | – | 91.7% | Annual Report of Certified Head and Neck Tumor Centers 2016 — Quality Indicators (in German) doi:10.13140/RG.2.1.2788.7609 |
CNS tumors | Interdisciplinary case discussions (numerator: primary cases [elective patients: pre-interventional, emergency patients: post-interventional] presented at the tumor conference; population: primary cases), indicator not derived from clinical guidelines | ≥ 95% | 68.4% (13/19) | 96.4% | Annual Report of Certified Neuro-Oncological Tumor Centers 2016 — Quality Indicators (in German) doi:10.13140/RG.2.1.2788.7609 |
Pancreas | Lymph-node examination (numerator: primary surgical cases of pancreas with ≥10 regional lymph nodes in the surgical specimen after completion of surgical treatment; population: primary surgical cases in pancreas (OPS 5–524 ff., 5–525 ff. only with ICD-10 C25) who have undergone lymphadenectomy) | No target value in 2015 | – | 90.0% | Annual Report of Certified Neuro-Oncological Tumor Centers 2016 — Quality Indicators (in German) doi:10.13140/RG.2.1.2788.7609 |